ALKS(Alkermes plc) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $1.17B | $1.11B | $1.66B | $1.56B | $1.48B |
| 毛利润 | $976.43M | $893.73M | $1.41B | $1.31B | $1.28B |
| 营业利润 | $97.75M | −$6.09M | $414.12M | $420.64M | $253.96M |
| 净利润 | −$48.17M | −$158.27M | $355.76M | $367.07M | $241.66M |
| 经营现金流 | $101.72M | $21.04M | $401.35M | $439.12M | $520.75M |
| 自由现金流 | $73.69M | −$17.21M | $353.31M | $405.64M | $480.33M |
| 摊薄每股收益 | $-0.29 | $-0.97 | $2.10 | $2.17 | $1.43 |